Akero Therapeutics, Inc. (AKRO)
Dec 9, 2025 - AKRO was delisted (reason: acquired by NVO)
54.65
0.00 (0.00%)
Inactive · Last trade price on Dec 8, 2025
Akero Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 176.03 | 340.24 | 234.21 | 249.77 | 150.48 | 187.24 |
Short-Term Investments | 561.79 | 402.84 | 315.8 | 101.68 | 37.78 | 81.15 |
Cash & Short-Term Investments | 737.83 | 743.08 | 550.01 | 351.45 | 188.26 | 268.39 |
Cash Growth | 2.87% | 35.10% | 56.50% | 86.69% | -29.86% | 96.77% |
Other Current Assets | 16.71 | 27.3 | 9.95 | 3.72 | 5.32 | 2.96 |
Total Current Assets | 754.54 | 770.38 | 559.96 | 355.17 | 193.58 | 271.35 |
Net Property, Plant & Equipment | 0.55 | 0.76 | 1.03 | 1.29 | 1.55 | 1.79 |
Long-Term Investments | 250.49 | 54.75 | 19.28 | - | - | - |
Other Long-Term Assets | - | - | - | 0.11 | 0.42 | 0.2 |
Total Assets | 1,006 | 825.89 | 580.27 | 356.57 | 195.55 | 273.34 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 20.4 | 9.03 | 7.04 | 7.97 | 6.71 | 3.43 |
Accrued Expenses | 27.25 | 30.73 | 12.09 | 11.12 | 18.42 | 9.68 |
Total Current Liabilities | 47.65 | 39.75 | 19.13 | 19.08 | 25.13 | 13.11 |
Long-Term Debt | - | 35.3 | 24.96 | 9.54 | - | - |
Long-Term Leases | 0.29 | 0.53 | 0.82 | 1.08 | 1.31 | 1.52 |
Other Long-Term Liabilities | - | 0.19 | 0.05 | 0.31 | - | - |
Total Long-Term Liabilities | 0.29 | 36.02 | 25.84 | 10.93 | 1.31 | 1.52 |
Total Liabilities | 47.94 | 75.77 | 44.97 | 30.01 | 26.44 | 14.63 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 |
Additional Paid-in Capital | 2,005 | 1,575 | 1,109 | 748.86 | 479.44 | 468.24 |
Accumulated Other Comprehensive Income | 1.83 | 0.95 | 0.27 | 0.04 | -0.03 | -0 |
Retained Earnings | -1,049 | -826.16 | -574.1 | -422.34 | -310.3 | -209.53 |
Shareholders' Equity | 957.64 | 750.11 | 535.31 | 326.56 | 169.11 | 258.71 |
Total Liabilities & Equity | 1,006 | 825.89 | 580.27 | 356.57 | 195.55 | 273.34 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 0.29 | 35.83 | 25.78 | 10.62 | 1.31 | 1.52 |
Net Cash (Debt) | 737.54 | 707.25 | 524.23 | 340.83 | 186.95 | 266.87 |
Net Cash Growth | 8.22% | 34.91% | 53.81% | 82.31% | -29.95% | 95.65% |
Net Cash Per Share | 9.43 | 10.53 | 9.97 | 8.74 | 5.37 | 8.48 |
Book Value | 957.64 | 750.11 | 535.31 | 326.56 | 169.11 | 258.71 |
Book Value Per Share | 12.24 | 11.17 | 10.18 | 8.38 | 4.86 | 8.22 |
Tangible Book Value | 957.64 | 750.11 | 535.31 | 326.56 | 169.11 | 258.71 |
Tangible Book Value Per Share | 12.24 | 11.17 | 10.18 | 8.38 | 4.86 | 8.22 |